Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole.

Authors:
Kukulka M; Nudurupati S; Perez MC.

Journal:
Therap Adv Gastroenterol

Publication Year: 2016

DOI:
10.1177/1756283X16670073

PMCID:
PMC5076779

PMID:
27803731

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Therap Adv Gastroenterol

Abbreviation: Therap Adv Gastroenterol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology & Hepatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and…
Li M; Chen S; Li S and 13 more (2024) - Transparency Score: 3/6
Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in in…
Nigam GB; Chatten K; Sharara A and 6 more (2024) - Transparency Score: 4/6
Chemotherapy combined with targeted therapy and immunotherapy is an option in advanced biliary trac…
Ge P; Wu Y. (2024) - Transparency Score: 3/6
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with u…
Calafat M; Torres P; Tosca-Cuquerella J and 56 more (2024) - Transparency Score: 3/6
Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should <i>K…
Béchade D; Palmieri LJ; Bonhomme B and 7 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest statement: The authors declare that there is no conflict of interest."

Evidence found in paper:

"Funding: All authors are employees of Takeda Development Center Americas, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals America, Inc. Funding for this study was provided by Takeda Development Center Americas, Inc."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025